Plan B Ruling: Little Commercial Impact, Big Policy Implications
This article was originally published in The Tan Sheet
Executive Summary
The court ruling overturning FDA's restricted distribution of the emergency contraceptive Plan B could have a number of implications for the biopharma industry - ranging from a near-term impact on confirmation of Obama administration nominees to a longer-term curbing of creative product risk management activities
You may also be interested in...
Comments Make Clear Jewish Women’s Group Supports OTC Daily Oral Contraceptive Approval
Religious groups commonly respond to proposals in US for birth control drugs or services, usually in opposition. But members of the National Council of Jewish Women are using form letters for comments supporting making a daily oral contraceptive drug available OTC.
Age-Restriction Labeling, Behind-The-Counter Sales Likely In HRA's US OTC Contraceptive NDA
“I think the issue is whether it is going to have age restricted labeling, which would be a political issue rather than a medical issue,” says
Political Winds, Like Previous Storms Over US FDA Decisions, Stir Around OTC Contraceptive Proposal
Experts spoke with HBW Insight about potential impact on US contraceptive market from Supreme Court’s decision in Dobbs v. Jackson overturning its 1973 ruling in Roe v. Wade, which was upheld in 1992 ruling in Planned Parenthood v. Casey, stating a woman has a constitutional right to reproductive health services.